INS and Obesity: Thus, to date, pharmacological evidence suggests that metabolic improvements induced by anti-obesity drugs (orlistat, sibutramine and rimonabant), insulin sensitizers (metformin and thiazolidinediones) and endocannabinoid receptor antagonists could be attributed, at least in part, to the induction of high plasma levels of adiponectin [81,82,83,84].